Brighter receives SEK 0.8 M through exercise of warrants.
The exercise period for Brighter’s warrants of series TO3 is now completed. The company thereby strengthens its financing with SEK 837 628, representing 209 407 new shares and votes.
Earlier this autumn Brighter received additionally SEK 29 M from the company's management, board and key personnel. The company also received SEK 2.9 M through exercise of TO4 warrants.
Those who subscribed in this exercise period have now obtained Interim Shares. Once the registration has been completed with the Swedish Companies Registration Office, conversion of the interim shares will automatically take place without further notice to the holders. The conversion is expected to occur within approximately one week from the completed registration. The interim shares will not be listed for trading.
For terms and conditions of the Warrants, please visit Brighter’s website: www.brighter.se.
For further information, please contact:
Truls Sjöstedt, CEO
Telefon: +46 709 73 46 00
Ann Zetterberg, CFO
Tel: +46 708 37 21 23
Brighter is a Swedish-based company that, from a unique IP portfolio, creates smart solutions for one of healthcare’s biggest challenges: changing patient behavior. Chronic diseases such as diabetes are rapidly increasing, and account for an increasing share of healthcare costs globally. Brighter's Business Model and Multi-Sided Market Platform - The Benefit Loop®- is based on the fact that many special interests create value for each other. By increasing access to valid health data, Brighter creates value for all stakeholders in the care chain: patients and their close associates, healthcare providers, research institutes, the pharmaceutical industry, and society as a whole. www.brighter.se
The Company's shares are listed on NASDAQOMX First North/BRIG. Brighter’s Certified Adviser on Nasdaq OMX First North is Eminova Fondkommission AB, +46 (0)8 – 684 211 00, email@example.com, www.eminova.se.
This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08:30 CET November 7, 2018.